$-0.39 EPS Expected for Aldeyra Therapeutics, Inc. (ALDX)

July 14, 2018 - By Jason Dias

Investors sentiment increased to 3 in 2018 Q1. Its up 1.38, from 1.62 in 2017Q4. It improved, as 3 investors sold Aldeyra Therapeutics, Inc. shares while 6 reduced holdings. 10 funds opened positions while 17 raised stakes. 10.28 million shares or 3.03% more from 9.98 million shares in 2017Q4 were reported.
Peddock Capital Advsrs Ltd Com holds 752 shares or 0% of its portfolio. 1.61M were accumulated by Fmr Limited Liability Company. Prelude Capital Management Ltd Liability Com accumulated 2,731 shares or 0% of the stock. Barclays Public Ltd Company holds 0% or 1 shares in its portfolio. Northern invested in 48,151 shares. Moreover, Hikari Power Limited has 0.1% invested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for 107,858 shares. Sphera Funds Mngmt owns 1.15% invested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for 1.01 million shares. New York-based Element Management Limited Liability has invested 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Millennium Mngmt Lc reported 753,143 shares. Knoll Capital Limited Partnership invested in 0.96% or 124,096 shares. Bluecrest Cap Mgmt Limited has 14,371 shares. State Street Corporation owns 0% invested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for 25,931 shares. 683 Mgmt Ltd Co accumulated 1.00M shares. Royal Commercial Bank Of Canada owns 40 shares or 0% of their US portfolio. Mangrove invested 0.16% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX).

Analysts expect Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) to report $-0.39 EPS on August, 14.They anticipate $0.04 EPS change or 11.43 % from last quarter’s $-0.35 EPS. After having $-0.43 EPS previously, Aldeyra Therapeutics, Inc.’s analysts see -9.30 % EPS growth. The stock increased 1.79% or $0.15 during the last trading session, reaching $8.55. About 94,454 shares traded. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has risen 82.11% since July 14, 2017 and is uptrending. It has outperformed by 69.54% the S&P500.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Coverage

Among 2 analysts covering Aldeyra Therapeutics (NASDAQ:ALDX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aldeyra Therapeutics had 4 analyst reports since January 26, 2018 according to SRatingsIntel. The stock of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has “Buy” rating given on Tuesday, May 15 by Cantor Fitzgerald. The firm has “Buy” rating given on Thursday, March 29 by Cantor Fitzgerald. The stock of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has “Buy” rating given on Tuesday, June 26 by Cantor Fitzgerald.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. The company has market cap of $171.94 million. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. It currently has negative earnings. The firm was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.

More recent Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) news were published by: Streetinsider.com which released: “Aldeyra Therapeutics (ALDX) Reports Last Patient Dosed in Dry Eye Disease Phase 2b Clinical Trial” on July 12, 2018. Also Prnewswire.com published the news titled: “Aldeyra Therapeutics Announces 2018 Research Day” on June 20, 2018. Prnewswire.com‘s news article titled: “Aldeyra Therapeutics Joins the Russell 3000® and 2000® Indexes” with publication date: June 25, 2018 was also an interesting one.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.